K. Taku

发表

Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.

K. Muro, N. Boku, T. Kojima, 2010, Japanese journal of clinical oncology.

Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin.

T. Nakajima, N. Boku, H. Yasui, 2015, Molecular and clinical oncology.

Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.

T. Yoshino, N. Boku, T. Kojima, 2009, Japanese journal of clinical oncology.

Nutrition Care in Internal Medicine

M. Shiraki, A. Kato, K. Taku, 2017 .

Risk factors and clinical courses of chemoradiation-related arterio-esophageal fistula in esophageal cancer patients with clinical invasion of the aorta

N. Boku, H. Yasui, T. Tsushima, 2011, International Journal of Clinical Oncology.

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).

M. Ando, E. Baba, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.

S. Yoshida, M. Asaka, A. Ohtsu, 2007, Japanese journal of clinical oncology.

Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer

H. Doyama, K. Tsuji, K. Mori, 2018, International Journal of Clinical Oncology.

OPTIMAL TIMING OF ENDOSCOPIC EVALUATION OF THE PRIMARY SITE OF ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY OR RADIOTHERAPY: A RETROSPECTIVE ANALYSIS

T. Hashimoto, H. Ono, N. Hasuike, 2009, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer

K. Muro, T. Satoh, Xiaojin Shi, 2012, Cancer Chemotherapy and Pharmacology.

Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients

N. Boku, T. Kojima, A. Tamiya, 2009, International Journal of Clinical Oncology.

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)

N. Sugimoto, I. Hyodo, H. Shinozaki, 2017, Gastric Cancer.

Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer

N. Boku, S. Hironaka, H. Yasui, 2010, Gastric Cancer.

A long-surviving case of gastric cancer with main portal vein tumor thrombus after surgical resection and postoperative S-1 therapy

Makoto Suzuki, H. Kanemoto, Shinsuke Sato, 2016, Clinical Journal of Gastroenterology.

Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis

N. Boku, S. Hironaka, H. Yasui, 2010, International Journal of Clinical Oncology.

Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination

N. Boku, T. Kojima, S. Hironaka, 2009, Gastric Cancer.

Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin

N. Boku, T. Kojima, S. Hironaka, 2009, Gastric Cancer.

Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).

A. Ono, T. Yoshino, H. Yasui, 2009, Japanese journal of clinical oncology.

Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.

N. Boku, T. Kojima, S. Hironaka, 2008, Japanese journal of clinical oncology.

Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer

T. Hashimoto, K. Taira, T. Yoshino, 2008, Journal of Gastroenterology.

Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine

Kazuyuki Inoue, D. Tsuji, K. Itoh, 2017, European Journal of Clinical Pharmacology.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Leptomeningeal carcinomatosis associated with gastric cancer

Y. Nakasu, N. Boku, H. Yasui, 2012, International Journal of Clinical Oncology.

Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors

S. Akinaga, T. Naito, N. Yamamoto, 2013, Cancer science.

Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

S. Yoshida, T. Yano, K. Nihei, 2011, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Prognostic Factors in Patients with Unresectable Pancreatic Cancer Treated with Gemcitabine: A Retrospective Analysis

Kazuyuki Inoue, H. Hayashi, D. Tsuji, 2014 .

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)

Kazuhiro Yoshida, T. Yoshikawa, E. Oki, 2018, Gastric Cancer.

Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine

D. Tsuji, K. Itoh, Y. Kawasaki, 2017, European Journal of Clinical Pharmacology.

S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.

N. Boku, S. Hironaka, H. Yasui, 2010, Japanese journal of clinical oncology.

Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients

N. Boku, H. Yasui, K. Yamazaki, 2013, International Journal of Clinical Oncology.

Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial

D. Tsuji, Yong-Il Kim, T. Daimon, 2012, Supportive Care in Cancer.

Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer

A. Takashima, D. Takahari, T. Nakajima, 2019, Gastric Cancer.

Long-Term Survival by Resection and Adjuvant Chemotherapy With S-1 in Pancreatic Signet Ring Cell Carcinoma: a Case Report With Literature Review

Makoto Suzuki, H. Kanemoto, T. Toda, 2020 .

Prostate cancer recurring as small‐cell carcinoma with a BRCA2 somatic mutation

Makoto Suzuki, K. Yoshimura, K. Taku, 2022, IJU case reports.

Retrospective Analysis of Severe Neutropenia in Patients Receiving Concomitant Administration of Docetaxel and Clarithromycin

H. Hayashi, D. Tsuji, K. Itoh, 2014, Chemotherapy.

Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer

N. Boku, S. Hironaka, H. Yasui, 2013, International Journal of Clinical Oncology.

Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.

N. Boku, T. Kojima, H. Yasui, 2010, Japanese journal of clinical oncology.

Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.

M. Asaka, T. Yoshino, N. Boku, 2008, Japanese journal of clinical oncology.

Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors

S. Akinaga, T. Naito, N. Yamamoto, 2013, Cancer science.

Enrichment of Immune-Related Genes in Aggressive Primary Breast Angiosarcoma: A Case Report

Makoto Suzuki, K. Kinoshita, J. Chan, 2023, Case Reports in Oncology.